Pregnancy outcome of a transfusion-dependent thalassemic woman

Pafumi, C.; Zizza, G.; Caruso, S.; Todaro, A. M.; Pernicone, G.; Bandiera, S.; Farina, M.; Russo, A.
October 2000
Annals of Hematology;Oct2000, Vol. 79 Issue 10, p571
Academic Journal
A clinical case concerning a normal pregnancy outcome in a transfusion-dependent woman affected by homozygous beta thalassemia, whose partner was negative with regard to the “thalassemic trait”, was reported. The patient showed no iron deposit problems, viral diseases that could have made the pregnancy management difficult or any complications during the gestation. Blood transfusion was not necessary during the following caesarean delivery. The outcome was a healthy female child, born at a gestational age of 38 weeks, showing neither malformations nor problems. This was possible due to a detailed preconceptual guidance and a pre-pregnancy assessment. The patient normally would have had a blood transfusion every 20 days and a strict desferrioxamine chelating therapy; however, this treatment was suspended during her pregnancy because of the well-recognised teratogenic effects of the drug. The average values of ferritin were just a little higher than before being pregnant. The foetus, due to her particular chelating activity, probably maintained these ferritin levels. A sample of 95 ml umbilical cord blood was taken during the delivery. It is well known that umbilical cord blood contains a good quantity of CD34+ stem cells, the haematopoietic progenitors. It was therefore collected for transplanting to the mother and for bone marrow reconstitution. Moreover, our experience suggests that desferrioxamine therapy during lactation does not alter iron excretion in breast milk. Therefore, women now affected by Cooley disease may possibly have a normal pregnancy without ovulation induction, intrauterine growth retardation, foetal loss and preterm labour.


Related Articles

  • Model-Based Optimisation of Deferoxamine Chelation Therapy. Bellanti, Francesco; Del Vecchio, Giovanni; Putti, Maria; Cosmi, Carlo; Fotzi, Ilaria; Bakshi, Suruchi; Danhof, Meindert; Della Pasqua, Oscar // Pharmaceutical Research;Feb2016, Vol. 33 Issue 2, p498 

    Purpose: Here we show how a model-based approach may be used to provide further insight into the role of clinical and demographic covariates on the progression of iron overload. The therapeutic effect of deferoxamine is used to illustrate the application of disease modelling as a means to...

  • autohemotherapy.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p218 

    A definition of the medical term "autohemotherapy," which refers to a treatment by withdrawal and injection intramuscularly of one's own blood, is presented.

  • Μέθοδοι αποσιδήρωσηϛ: μια βιβλιογραφική... Maria, Agapiou; Elpida, Georgiadi // Rostrum of Asclepius / Vima tou Asklipiou;jan-mar2012, Vol. 11 Issue 1, p5 

    "Iron Chelation Therapy" is a term used to describe the procedure of removing excess iron from the body, which is applied after a total of approximately 20 blood transfusions or when serum ferritin levels rise above 1000 ng/ml. Aim: The purpose of the present paper is a retrospective search in...

  • High serum ferritin. Crowther, Mark; Watson, Henry G. // GP: General Practitioner;8/31/2007, p28 

    The article presents information related to the management of raised serum ferritin. Raised serum ferritin can be caused by damage to ferritin-containing tissues, inflammation or infection, secondary iron-loading condition and chronic anaemias. Serum ferritin due to tissue damage or as part of...

  • Demyelinating butterfly pseudo-glioma. Scozzafava, J.; Johnson, E. S.; Blevins, G. // Journal of Neurology, Neurosurgery & Psychiatry;Jan2008, Vol. 79 Issue 1, p12 

    The article provides information on the study concerning the demyelinating butterfly pseudo-glioma in Great Britain. On the examination of a 27-year-old woman who had a 2-month history of progressive headache, nausea, vomiting, and deterioration in memory, her vital signs were normal but there...

  • Prevalence of Du Phenotype amongst Rhesus Negative Females in Pott Harcourt, Nigeria. Nwauche, C. A.; Ejele, O. A.; Okpani, A. O. U. // African Journal of Reproductive Health;Apr2003, Vol. 7 Issue 1, p27 

    The prevalence of Du phenotype was investigated among rhesus negative women of childbearing age (15-45 years) in Port Harcourt, Nigeria, over a period of 17 months. A total of 1,108 women were randomly sampled, out of which 1,003 (90.5%) were rhesus positive and 105 (9.5%) rhesus negative. Only...

  • Large uterus doesn't preclude abdominal myomectomy.  // Contemporary OB/GYN;Apr2006, Vol. 51 Issue 4, p16 

    Reports on the results of a study regarding the effective management of women with uterine fibroids that is the size of or larger than 16 weeks in size via abdominal myomectomy in the U.S. in 2006. Identification of 236 minutes of operating time in 91 myomectomies that were observed; Need for...

  • Febrile Nonhemolytic Transfusion Reactions. Baldwin, Patricia Donahue // Clinical Journal of Oncology Nursing;May/Jun2002, Vol. 6 Issue 3, p1 

    Provides an overview of febrile nonhemolytic transfusion reactions (FNHTR). Definition of FNHTR; Incidence and risk factors; Pathophysiology of such reactions; Treatment.

  • Severe iron overload and hyporegenerative anemia in a case with rhesus hemolytic disease: therapeutic approach to rare complications. Demircioğlu, Fatih; Sózmen, Şule Çağlayan; Yılmaz, Şebnem; Ören, Hale; Arslan, Nur; Kumral, Abdullah; Özer, Erdener; İrken, Gülersu // Turkish Journal of Hematology;Sep2010, Vol. 27 Issue 3, p204 

    A 33 weeks' gestation, a baby with rhesus hemolytic disease (RHD), who had received intrauterine transfusions twice, developed cholestatic hepatic disease and late hyporegenerative anemia. Her serum ferritin and bilirubin levels increased to 8842 ng/ml and 17.9 mg/dl, respectively. Liver biopsy...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics